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ABSTRACT
Oncolytic viruses selectively target and replicate in cancer cells, providing us 
with a unique tool with which to target and kill tumour cells. These viruses come 
from a diverse range of viral families including reovirus type 3 Dearing (RT3D), a 
non-pathogenic human double-stranded RNA oncolytic virus, which has been shown 
to be an effective therapeutic agent, both as a mono-therapy and in combination 
with traditional chemotherapeutic drugs. This study investigated the interaction 
between RT3D and radiotherapy in melanoma cell lines with a BRAF mutant, Ras 
mutant or BRAF/Ras wild type genotype. The data indicates that RT3D combined 
with radiotherapy significantly increased cytotoxicity relative to either single agent, 
independent of genotype, both in vitro and in vivo. The mechanism of enhanced 
cytotoxicity was dependent on an increase in viral replication, mediated by CUG2 
up-regulation and subsequent down-regulation of pPKR and p-eIF2α, leading to the 
activation of mitochondrial apoptotic signalling resulting in increased cell death.
INTRODUCTION
Oncolytic viruses selectively target and kill cancer 
cells, leaving untransformed cells unaffected. This unique 
ability has been exploited in recent years, with a number 
of viruses including reovirus type 3 Dearing (RT3D) [1], 
Newcastle disease virus [2], herpes simplex virus type I 
[3] and coxsackievirus A21 [4] having been extensively 
studied for their therapeutic potential.
Reovirus has been extensively researched over 
recent decades, resulting in the intensive clinical testing 
now published in numerous multicentre phase I/II clinical 
trials [5] [6] [7] [8]. Initial Phase I monotherapy studies 
established reovirus as a safe clinical agent, although with 
insufficient anti-tumor activity to make it a successful 
stand-alone therapy [9] [10] [11]. However, recent pre-
clinical and clinical testing has produced significant 
evidence showing a higher efficacy for reovirus when 
combined with traditional chemotherapeutic agents 
such as cisplatin [12], docetaxel [13] and as a triple 
combination with cisplatin and paclitaxel [14]. More 
recently, reovirus has also been shown to have enhanced 
activity when combined with BRAF and MEK inhibitors 
in melanoma [15].
The potential of combining reovirus with RT was 
initially described in in vitro and in vivo pre-clinical studies 
[16]. This work showed that the combination effect was 
particularly significant in cell lines which were relatively 
resistant to reovirus alone, although the mechanism of 
this enhanced effect was not fully elucidated. The study 
also assessed criteria relevant for clinical implementation 
of this combination therapy, showing that the virus itself 
was resistant to high doses of irradiation, ensuring that 
it would not be inactivated during treatment and that 
the enhanced cytotoxic effect was neither schedule- nor 
sequence-dependent. A subsequent Phase I clinical trial 
established that the combination of intratumoral reovirus 
and radiotherapy was tolerable and safe in patients with 
advanced cancers. There was also evidence of local 
efficacy and response in distant unirradiated disease [17].
In the current study, we build on the existing 
evidence and investigate the mechanism underlying the 
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enhanced therapeutic efficacy of combining reovirus 
and RT in melanoma. Our data suggest that enhanced 
cytotoxicity is mediated through increased viral replication 
and activation of mitochondrial apoptotic signalling.
RESULTS
RT3D and RT combination shows synergistic 
cytotoxicity in melanoma
The effect of RT3D and RT combination therapy 
was assessed in multiple melanoma cell lines of various 
genetic backgrounds, including V600EBRAF mutant, Ras 
(K- and N-) mutant and BRAF/Ras wild-type (WT). Cells 
were either treated with RT3D alone or irradiated with 
either 3 or 5 Gy fractions and 4 hours later infected with 
RT3D at a range of MOIs (multiplicity of infection). The 
effects of both monotherapy and combination therapies 
were assessed 72 hours later by both MTT and crystal 
violet assay (Figure 1A, 1B). The N-Ras mutant DO4 
cell line displayed high levels of sensitivity to the virus 
alone, compared to the K-Ras mutant cell line, WM1791c, 
which was resistant to the virus both as monotherapy or 
in combination with RT. Both V600EBRAF mutant and WT 
cell lines displayed significantly enhanced cytotoxicity in 
the combination therapy groups; with V600EBRAF mutant 
A375 and WT PMWK cell lines the most sensitive to the 
combination therapy, especially at the higher dose (5 Gy) 
of irradiation. To evaluate the level of synergy between 
RT3D and RT, we used Bliss independence analysis. The 
results from the Bliss analysis showed no synergy in either 
of the Ras mutant cell lines. However both BRAF mutant 
(A375 and Mel624) and WT (PMWK and MeWo) cell 
lines displayed a strong synergistic effect (Figure 1C).
RT3D and RT combination therapy enhances 
cytotoxicity through mitochondrial apoptotic 
signalling
A human apoptosis array was carried out in the 
BRAF mutant A375 cell line 72hrs after treatment under 
the following conditions: untreated; 5 Gy irradiation; 
RT3D at MOI 0.01; and 5 Gy + RT3D at MOI 0.01 
(Figure 2A). Densitometry analysis was carried out on the 
resulting images using Image J software and differences 
in the intensity of each antibody under each condition 
was graphed (Figure 2A). Analysis of the array showed 
a strong increase in the expression of cleaved caspase 3 
in the combination group compared to either virus or RT 
alone. Enhanced caspase 3 cleavage was confirmed in the 
A375 cell line by western blot, with a similar effect also 
observed in the second BRAF mutant cell line Mel624 and 
the WT cell line PMWK (Figure 2B).
The combination therapy clearly displayed a 
predilection for modulating mitochondrial apoptotic 
signalling (graphs and western blots of extrinsic apoptotic 
signalling are shown in Supplementary Figure S1A, 
S1B). The combination therapy had a clear effect on the 
Bcl2 family of proteins, by down-regulating pro-survival 
proteins, such as Bcl2 and Bcl-XL, while up-regulating 
the pro-apoptotic protein Bax (Figure 2A). Western blot 
analysis also indicated the down-regulation of pro-survival 
Bcl2 and Bcl-XL and the up-regulation of pro-apoptotic 
Bax (Figure 2B).
The array also revealed down-regulation of the 
inhibitor of apoptosis (IAP) family of proteins which 
inactivate caspases. Western blot confirmed a decrease in 
XIAP, cIAP1 and cIAP2, observed in multiple cell lines, 
with a corresponding increase in cleaved caspase 9 and 
caspase 3 (Figure 2B).
Surprisingly, the array data seemed to indicate a 
decrease in the levels of mitochondrial pro-apoptotic 
proteins such as Smac/Diablo and cytochrome c 
(Figure 2A). We subsequently used confocal imaging 
and mitochondria/cytoplasm fractionation in A375 cells 
to determine if cytochrome c and Smac/Diablo were 
released from the mitochondria (Supplementary Figure 
S1C, S1D). Our results suggest that treatment with RT3D 
alone can release cytochrome c and Smac/Diablo from the 
mitochondria. While this may be enhanced by the addition 
of RT the effect appears to be primarily a viral response.
RT enhances RT3D viral replication by 
inhibiting PKR activation mediated by CUG2
Viral replication was measured by both one-step 
growth curves and plaque assays. Cells were irradiated at 
either 3 or 5 Gy fractions and 4 hours later infected with 
RT3D at MOI of 5. Viral replication was assessed at 4, 24 
and 48 hours by one-step growth curves (Figure 3A) and at 
48 hours by viral plaque assay (Supplementary Figure S2). 
Both the growth curves and plaque assays showed a clear 
increase in replication for all cell lines, with the exception 
of the K-Ras mutant WM1791c cell line. There was a clear 
increase in replication for the BRAF mutant cell lines, 
A375 and Mel624, at both 24 and 48 hours in the viral 
growth curves and the plaque assays at 48 hours. The WT 
cell lines, PMWK and MeWo, also showed a significant 
increase in replication, particularly at 48 hours, on both 
assays (Figure 3A).
In order to determine how RT was leading to an 
increase in RT3D viral replication, we examined the 
expression of proteins known to play a role in RT3D 
viral replication. Increased expression of cancer up-
regulated gene 2 (CUG2) has previously been reported 
to enhance RT3D viral replication [18]. Upregulation of 
CUG2 was observed for both BRAF mutant cell lines 
and the WT PMWK cell line following RT3D and RT. 
This was associated with a corresponding decrease 
in pPKR and p-eIF2α expression, allowing for the 
enhanced translation of viral proteins as demonstrated 
by increased expression of reoviral outer capsid protein, 
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Figure 1: RT3D and RT combination in a panel of melanoma cell lines. Cells were irradiated at either 3 or 5 Gy and 4 hours 
later infected with RT3D at a range of MOIs. Cell survival was measured by MTT A. and confirmed by crystal violet assay B. Synergy was 
assessed using Bliss analysis C.
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Figure 2: RT3D and RT combination therapy increases apoptosis in melanoma cells. Human apoptosis array was used to 
assess expression levels of pro - and anti – apoptotic proteins in A375 cells. Cells were either untreated, infected with RT3D (MOI 0.1), 
irradiated (5 Gy) or treated with a combination of RT3D (MOI 0.1) and 5 Gy irradiation. Array membranes were analysed using Image J to 
determine differences in expression levels of proteins A. Results from array were confirmed by western blotting and expression was also 
assessed in the complete panel of melanoma cells B.
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Figure 3: RT increases RT3D viral replication in melanoma cells through the suppression of PKR activation. Cells were 
irradiated at either 3 or 5 Gy and 4 hours later infected with RT3D (MOI 5). The cells were harvested and supernatant was collected at 4, 
24 and 48hr after infection. Viral titres were assessed using one - step growth curve assays A. Cells were irradiated at 5 Gy and 4 hours 
later infected with RT3D (MOI 5). Expression of CUG2, pPKR, p-eIF2α and viral protein µ1c were detected by western blotting at 48hr B.
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µ1c (Figure 3B). The N-Ras mutant DO4 cell line 
also showed an increase in CUG2 and downstream 
decrease in pPKR and p-eIF2α, although the effect 
was less pronounced. In the K-Ras mutant cell line 
WM1791c, consistent with the viral replication data, 
the combination therapy did not upregulate CUG2 and 
both PKR and eIF2α remained highly phosphorylated 
(Figure 3B). The WT MeWo cell line did not show 
an increase in CUG2. However PKR activation was 
inhibited in this cell line as levels of pPKR and p-eIF2α 
were decreased. This suggests that, in MeWo cells at 
least, PKR inactivation may be mediated by a protein 
other than CUG2.
RT-induced RT3D viral replication is reversed 
by the inhibition of either Ras or p38
The initial study proposing a role for CUG2 in 
reoviral replication [18] determined that CUG2 worked 
through the activation of Ras and p38 signalling. We, 
therefore, hypothesized that if RT was enhancing 
replication through a CUG2-Ras-p38 signalling cascade 
inhibition of either Ras or p38 should prevent RT-
induced viral replication. We also hypothesized that, 
in line with the initial study, inhibition of other MAPK 
proteins, such as ERK, should not greatly affect RT-
induced replication. BRAF mutant A375 cells were 
used in this experiment. Cells were pre-treated with 
either salirasib (10 µM), p38 inhibitor IV (10 µM) or 
PD184352 (1 µM) 1 hour before irradiation at 5 Gy. 
Cells were then infected with RT3D (MOI 5) 4 hours 
after irradiation, consistent with previous replication 
assays. Replication was measured by one-step growth 
curve assays. Protein was isolated under the same 
conditions at 48 hours for western blot analysis. Pre-
treatment of cells with either salirasib or p38 inhibitor IV 
significantly reduced RT-induced replication returning 
it to baseline levels (Figure 4A and 4B). Pre-treatment 
with the PD compound also had an effect on RT-induced 
replication, albeit to a much lesser extent compared to 
either of the other inhibitors (Figure 4C). In correlation 
with the replication data, both pPKR and p-eIF2α 
showed consistently high phosphorylation levels in the 
combination group when pre-treated with either Salirasib 
or p38 inhibitor IV. The pre-treated combination group 
for these two inhibitors also displayed lower expression 
of both viral µ1c and cleaved caspase 3, indicating 
a link between increased viral replication and cell 
death (Figure 4A and 4B). Pre-treatment with the PD 
compound, however, appeared to have little effect on 
the phosphorylation levels of both PKR and eIF2α or 
the high levels of µ1c and cleaved caspase 3, despite its 
effects on viral replication (Figure 4C). Taken together 
these results support previous reports that signalling 
through Ras and p38, but not ERK, is needed for CUG2-
associated viral replication.
Inhibition of RT3D viral replication decreases 
apoptotic signalling
To explore the link between replication and 
apoptosis, replication was curtailed by binding the virus 
to the monoclonal antibody 4F2 (which targets sigma 3 
protein), before infection of cells. Previous studies [19, 
20] established that 4F2 inhibits the production of virus 
particles by blocking virus replication. Viral replication 
was measured by one-step growth curves in A375 and 
MeWo (BRAF mutant and WT, respectively) cell lines. 
The effect of radiotherapy on replication was diminished 
in both cell lines when the virus was pre-incubated with 
4F2 antibody (Figure 5A). In order to ensure that the 
decrease in replication was not due to the 4F2 antibody 
blocking viral entry into the cell, both qPCR and a one-
step PCR assay were carried out using RNA collected 
from the 4hr time point. Pre-incubation with 4F2 antibody 
did lower the copy number for the RT sample in both cell 
lines however the difference was not significant. PCR 
products from the one-step assay, visualized on an agarose 
gel, showed strong bands in all the samples. Both these 
assays indicated that the antibody did not prevent viral 
entry into the cell (Figure 5B). Analysis of cleaved caspase 
3 signalling indicated that there was also a decrease 
in the level of apoptosis across the cell lines when the 
virus was pre-incubated with 4F2 antibody (Figure 5C). 
These results suggest that the increase in replication and 
enhanced apoptosis do not occur independently of each 
other, but rather are linked with the enhanced replication 
promoting apoptosis.
Combined RT3D and RT therapy in vivo 
prolongs survival in A375 V600EBRAF mutant 
xenograft tumours
As a result of the potential therapeutic efficacy of 
combining RT3D and RT observed in the in vitro study, 
we assessed the therapeutic potential of this combination 
in vivo. A375 xenograft tumours were established in 
CD1 nude mice. Mice were randomly allocated into 
the following groups: untreated; RT3D alone at 1 x 106 
plaque forming units (PFU); RT alone (6 Gy in three 
fractions over 5 days); and a combination of 6 Gy in 
three fractions plus 1 x 106 PFU RT3D. The treatment 
timeline is summarised in Figure 6A. One mouse from 
each group was culled at the end of treatment on day 
5 for pharmacodynamics analysis. Tumour volume 
from the remaining mice in each group was measured 
and % volume change was plotted to day 80 after 
treatment (Figure 6B). While RT3D monotherapy did 
delay tumour growth and prolonged survival compared 
to RT monotherapy, the combination therapy was 
significantly more effective than either monotherapy 
at delaying tumour growth. Survival analysis for the 
combination cohort also showed that these mice had a 
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Figure 4: RT-induced viral replication is reversed by inhibition of either Ras or p38. A375 cells were treated with salirasib 
(10 µM) A., p38 inhibitor IV (10 µM) B. or PD184352 (1 µM) C., 1hr before irradiation at 5 Gy and 5 hrs before infection with RT3D 
(MOI 5). Viral titres were assessed by one - step growth curve assays (A-C). Protein was isolated at 48hrs and expression of CUG2, pPKR, 
p-eIF2α, cleaved caspase 3 and viral protein µ1c were detected by western blotting (A-C). Expression of Ras (A), p-p38 (B) and pERK (C) 
were also assessed.
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lower mortality rate compared to either monotherapy 
or control cohorts (Figure 6C). Consistent with in vitro 
data, western analysis showed enhanced mitochondrial 
apoptotic signalling in the combination group resulting 
in increased caspase 3 cleavage. An increase in the 
expression of viral outer capsid proteins µ1c and sigma 
3 indicated enhanced viral replication - also consistent 
with in vitro data (Figure 6D).
Figure 5: Inhibition of RT3D viral replication decreases apoptotic signalling. RT3D was pre-incubated with 4F2 antibody 
overnight at 4°C. A375 and MeWo cell lines were irradiated at 5 Gy and 4 hours later infected with either RT3D (MOI 5) or RT3D + 4F2 
antibody (MOI 5). The cells were harvested at 4, 24 and 48hr after infection and viral titres assayed by one - step growth curve assay A. 
Viral RNA was isolated from the 4 hr time point and analysed by both qPCR and a one – step PCR assay. PCR products were visualized on 
an agarose gel B. Protein was isolated at 48hrs and expression of cleaved caspase 3 was detected by western blotting C.
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Figure 6: Combined RT3D and RT therapy enhances tumour reduction in V600EBRAF mutant melanoma in vivo. A375 
subcutaneous xenograft tumours were established in CD1 nude mice. Mice were either untreated, irradiated with 2 Gy fractions for 3 cycles, 
RT3D infected at 1 x 106 pfu/ml or combined treatment (2 Gy fraction for 3 cycles and 1 x 106 pfu/mL RT3D) A. The size of tumours 
was measured for each treatment group and the % volume change for each group plotted. Each bar represents ±SEM of at least 8 mice. 
B. A Kaplan-Meier curve was used to assess median survival rate for each treatment group. C. Tumours were collected from one mouse per 
cohort on day 5 of treatment and levels of apoptotic proteins assessed by western blot. Protein was isolated from tumours and expression 
of Bcl2, Bcl-XL, XIAP, cIAP1, cleaved caspase 3, µ1c and sigma 3 were detected by western blotting D.
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DISCUSSION
Melanoma is one of the deadliest forms on skin 
cancer and is on the rise worldwide. A major obstacle 
in the treatment of malignant melanoma is its resistance 
to classical chemotherapy and radiotherapy, which may 
be due, in part, to a natural resistance to apoptosis [21] 
attributed to high levels of anti-apoptotic Bcl2 proteins 
[22]. In recent years, much progress has been made in 
understanding the genetic background of this disease 
and identifying specific targets for drug development. 
For instance, Ras/Raf/Mek signalling has come to the 
fore with the finding that up to 50% of melanomas have 
a BRAF mutation and up to 30% have a NRAS mutation 
[23] [24, 25], with resulting inhibitors targeting BRAF 
specifically [26] and MEK signalling in general [27].
Aside from traditional drug development strategies, 
other areas of research have focussed on the development 
of biological therapies including the use of oncolytic virus 
therapy. Numerous pre-clinical and clinical studies have 
been carried out using a diverse range of oncolytic viruses 
including vaccinia [28, 29], HSV [30], VSV [31] and 
reovirus [32], both as monotherapies or in combination 
with traditional anti-cancer agents. The recent successful 
phase III clinical trial of HSV [33] in melanoma and the 
subsequent FDA approval of the virus have highlighted 
the potential of oncolytic viruses as anti-cancer agents, 
especially in melanoma.
Utilizing our growing understanding of this disease, 
we assessed the therapeutic potential of combining RT3D 
and RT in a panel of melanoma cell lines which included 
BRAF mutant, Ras mutant and BRAF/Ras wild-type 
cells. Previous work carried out in our lab combining 
GLV-1h68 (oncolytic vaccinia virus) and RT showed 
a synergistic effect in BRAF mutant melanoma that is 
mediated through JNK and TNFα signalling [34]. In this 
current study, while a synergistic effect was observed in 
BRAF mutant cells, it was also present in the BRAF/Ras 
wild-type cells, indicating that any increased effect was 
independent of Ras/Raf genotype (Figure 1A–1C). This 
synergy indicated a potential therapeutic advantage for the 
combination therapy and so we explored the mechanism 
behind our observations.
Cell death can occur through various mechanisms, 
with reovirus having previously been shown to induce 
apoptosis by both the death receptor signalling pathway, 
mediated by TRAIL, and the intrinsic mitochondrial 
pathway [35–37]. We assessed apoptotic signalling in a 
panel of cell lines to determine which mechanism was 
in play. An apoptosis array carried out on BRAF mutant 
cells indicated that signalling was through the intrinsic 
mitochondrial apoptotic pathway rather than through 
receptor-mediated extrinsic signalling (Figure 2A, 2B). 
This result was confirmed across the panel of cell lines, 
with decreases in pro-survival and corresponding increases 
in pro-apoptotic Bcl2 proteins observed in the combination 
group. Co-ordinate decreases in the expression of inhibitor 
of apoptosis proteins and increases in both cleaved caspase 
9 and cleaved caspase 3 reinforced the argument that 
amplification of mitochondrial apoptotic signalling was 
the primary mechanism of cell death for the combination 
of RT3D and RT (Figure 2C).
Apoptosis can be triggered by various stress stimuli 
within the cell, in the case of invading viral particles an 
increase in viral replication is a widely accepted method 
of viral cell kill [13, 38]. While this does not always 
prove to be the case [39, 40], we hypothesized that the 
combination of RT and RT3D would result in an increase 
in viral replication, ultimately resulting in cell death. 
Our data clearly validated this hypothesis, with both 
one–step growth curves and plaque assays displaying a 
significant increase in viral replication with the addition 
of RT (Figure 3A, Supplementary Figure S2). When the 
virus was prevented from replication by pre-incubation 
with a sigma 3 antibody (4F2), we observed a decrease in 
cleaved caspase 3 signalling indicating reduced levels of 
apoptosis (Figure 5). The protective properties of various 
anti-reovirus monoclonal antibodies was first proposed by 
Virgin et al [20] who showed that these antibodies could 
inhibit the replication process at various stages, including 
binding to the cell, internalization or uncoating of the 
viral particle inside the cell. The sigma 3 antibody used 
in this study was found to act after the virus particle was 
bound to the cell and either at or before the un-coating of 
the viron. Therefore, for our study, equivalent amounts of 
virus particle were able to enter the cell regardless of the 
presence or absence of antibody, which was confirmed by 
PCR 4 hours after infection (Figure 5B). We can conclude, 
therefore, that decreased viral replication and subsequent 
decrease in apoptosis was not an effect of viral entry.
In order to confirm the therapeutic potential of RT 
and RT3D combination therapy, an in vivo study was 
carried out using a BRAF mutant A375 xenograft model. 
The in vivo results confirmed our in vitro observations with 
a significant increase in survival in the combination group 
and also the lowest percentage tumour volume change 
compared to the control group or either monotherapy 
group (Figure 6). Analysis of tumours isolated on day 
5 of the treatment regimen confirmed the activation of 
mitochondrial apoptotic signalling with a decrease in both 
pro-apoptotic Bcl2 proteins and IAP proteins, as well as 
an increase in cleaved caspase 3 proteins. An observed 
upregulation of reovirus protein µ1c in the combination 
group also indicated an increase in replication, again 
confirming the in vitro findings.
The logical question arising from these results 
is; how does RT contribute to the increase in RT3D 
replication? To answer this question, we decided to probe 
the host cell’s anti-viral defence mechanisms, in particular 
the activation of the PKR pathway. PKR is a protein that 
recognises and binds to double-stranded RNA molecules, 
resulting in auto-phosphorylation of the protein. This 
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phosphorylated PKR then phosphorylates eIF2α, which 
inhibits the host cell’s translational machinery preventing 
the translation of viral proteins (Figure 7A). A recent 
study by Park et al [18] showed that this pathway could be 
deactivated by the overexpression of the oncogene CUG2, 
through activation of the MAPK pathway, specifically Ras 
and p38, resulting in an increase in reovirus replication 
(Figure 7B). When we examined this signalling pathway 
in our panel of cell lines, there was evidence of activation 
in the combination group in the majority of cell lines. Both 
Figure 7: Proposed mechanism of action of RT3D + RT combination therapy. The PKR recognizes and binds to double-stranded 
RNA molecules resulting in its auto-phosphorylation and the subsequent downstream phosphorylation of eIF2α. The phosphorylation of 
eIF2α switches off the host cell’s translational machinery preventing viral protein translation A. RT3D prevents the phosphorylation of PKR 
leaving eIF2α in an un-phosphorylated state and the host cell’s translational machinery intact B. RT combined with up-regulates CUG2 
resulting in the activation of Ras and the downstream protein p38. The activation of this pathway switches off the PKR defence mechanism, 
allowing viral protein translation and increasing viral replication C. The increase in viral replication ultimately results in cell death via 
mitochondrial apoptotic signalling D.
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BRAF mutant and WT cell lines, which displayed the most 
significant RT-induced increase in replication (Figure 3), 
showed up-regulation of CUG2 in the combination group 
and a deactivation of the host’s anti-viral defences by 
decreased levels of both pPKR and p-eIF2α (Figure 3).
Although the up-regulation of CUG2 in the 
combination group implicated this pathway in RT-induced 
viral replication, further confirmation was needed. As 
previous reports suggested a role for MAPK activity in 
connection with CUG2 signalling, inhibitors of Ras, 
p38 and ERK were used to determine if the increase in 
replication could be reversed. As shown in Figure 4, 
inhibitors of either Ras (salirasib) or p38 (p38 inhibitor IV) 
significantly reduced the effect of RT on viral replication, 
returning levels to baseline. Inhibition of ERK, however, 
did not have the same dramatic effect, supporting previous 
work indicating a role for Ras and p38, but no other 
MAPK proteins, in CUG2-mediated reovirus replication 
(Figure 4).
Since it was first identified as an oncogene in 2007 
[41], CUG2 overexpression has been linked to apoptosis 
in ovarian cancer cells [42] and migration and drug 
resistance in colon cancer cells [43]. As it has also been 
shown to predominantly localize to the nucleus [44], 
there is no clear mechanism of cross-talk between CUG2 
and the activation of the pathways mentioned above. 
The previous report linking CUG2 and Ras to reovirus 
replication did not show if Ras activated CUG2 or 
vice versa. In our study, the inhibition of Ras by salirasib 
did not reduce the levels of CUG2, indicating that Ras 
does not induce CUG2 expression (Figure 4A). Although 
our data provide further evidence for the role of CUG2, 
Ras and p38 in reovirus replication, the precise mechanism 
of cross-talk within this signalling pathway remains to be 
fully elucidated.
Switching off the PKR pathway is an important 
viral tactic in breaching the host cell’s defences; however 
it is by no means the only weapon at its disposal. Recent 
work has highlighted the role of PTEN in anti-viral 
innate immunity by activating an interferon response. 
Specifically PTEN was found to control the import of 
the transcription factor IRF3 into the nucleus where it 
activates interferon –responsive genes [45] [46]. Li et al 
showed that PTEN deficient models, both in vitro and 
in vivo, were more susceptible to the oncolytic virus VSV 
due to a decrease in the induction of type 1 interferon 
reducing the anti-viral immune response. In an era of 
increased interest in understanding the complex interaction 
between the immune system and tumor cells it is possible 
that combining novel biological therapies with traditional 
agents will unlock new avenues of immune activation 
which can be manipulated to deliver a more targeted 
therapy and improve patient outcomes.
Reovirus is currently being tested as an anti-cancer 
therapy in phase I/II clinical trials. Previous studies, both 
pre-clinical and clinical, have shown that reovirus is more 
effective as a combination agent rather than a stand-alone 
therapy. Our research provides further evidence of the 
therapeutic potential of this agent and builds on previously 
published studies highlighting the benefits of combining 
this oncolytic virus with radiotherapy.
MATERIALS AND METHODS
Cell lines
The following cell lines (obtained from Prof. Richard 
Marais) were used: A375, Mel624, (V600EBRAF mutant), 
MeWo and PWMK (wild-type RAS and BRAF), D04 
(Q61LN-RAS mutant), WM17971c (Q61HK-RAS mutant) and 
L929 mouse fibroblasts (Oncolytics Biotech, Inc.). D04 
and WM1791c cells were cultured in RPMI (Roswell Park 
Memorial Institute) media, all other cells were cultured in 
DMEM (Dulbecco’s Modified Eagle’s Medium). Media 
were supplemented with 5% (v/v) FCS, 1% (v/v) glutamine, 
and 0.5% (v/v) penicillin/streptomycin.
Reovirus stocks
Reovirus Dearing type 3 (RT3D) stocks at 2.8 x 
109 tissue culture infectious dose 50 (TCID
50
/ml) were 
obtained from Oncolytics Biotech and stored at 1:10 
concentrations either in PBS or DMEM containing 5% 
(v/v) FCS, 1% (v/v) glutamine, and 0.5% (v/v) penicillin/
streptomycin at -80°C.
3-(4, 5-dimethylthiazol-2-yl)-2, 
5-diphenyltetrazolium bromide assay
Cell viability was quantified using a 3-(4, 
5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide 
(MTT) assay. 20 mL MTT (thiazolyl blue; Sigma-Aldrich) 
at 5 mg/mL in PBS was added to treated cells in a 96-
well plate for 4 hours at 37°C. Crystals were solubilised 
in DMSO and absorbance measured at 570 nm on a 
SpectraMax 384 plate reader (Molecular Devices).
Crystal violet survival assay
Cell viability was assessed by crystal violet staining 
(Sigma-Aldrich) at 0.2% (w/v) in a 7% (v/v) solution of 
ethanol/PBS. Plates were incubated at room temperature 
for 1 hour and then washed twice in distilled water. The 
crystal violet stained images of the plate were captured on 
a Microtek ScanMaker 8700 (Microtek International Ltd).
Replication assays
Melanoma cells were seeded in 24-well plates at 
a density of 1 x 105 cells/well. Culture plates were then 
irradiated at either 3 Gy or 5 Gy the next day and infected 
with RT3D at an MOI of 5 for 2 hours. The cells were 
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washed twice in complete growth media. Complete growth 
media was added to the cells and incubated at 37°C. The 
cells were harvested and the supernatants were collected 
at 4, 24, and 48 hours post-infection in triplicate. The 
lysates had three freeze-thaw cycles between −80°C 
and room temperature. For one-step growth curves the 
resulting lysates were titrated on L929 cells in 96-well 
plates. Viral titers were determined using the TCID
50
/
method as previously described [16]. For plaque assays, 
dilutions were used to infect L929 cells seeded at 2 x 
105 cells/well in 6 well plates. After incubation at 37°C 
for 4 hours, the viral medium was removed and the wells 
overlaid with a 1:1 solution of 2% agar (Sigma) and 2X 
DMEM containing 5% (v/v) FCS, 1% (v/v) glutamine, 
and 0.5% (v/v) penicillin/streptomycin. After 5 days, 
plates were stained with 0.2% crystal violet in 7% ethanol. 
Plates containing plaques were scanned and counted using 
OpenCFU software [47].
PCR
Viral RNA was extracted from the 4 hour 
replication time point using a Qiagen QIAamp Viral 
RNA kit. RNA isolated from stocks was used as a 
positive control. One step RT-PCR was then carried out 
using Qiagen One Step RT-PCR kit with the following 
primers; forward 5’GGGCTGCACATTACCACTGA 
3’, reverse 5’CTCCTCGCAATACAACTCGT 3’. PCR 
products were then resolved on a 2% agarose gel, stained 
with EtBr (Sigma) and visualized using a UV trans-
illuminator. Quantitative PCR was carried out on viral 
RNA samples using Bioline SensiFAST™ SYBR® Hi-
ROX One-Step Kit. The following primers were used; 
forward 5’ TTAGGATGGCCTCGTCCTTT 3’, reverse 
5’TTCATCATCACGCAAAACCT 3’. A standard curve 
was created using viral stock RNA. Copy number was 
calculated using online copy number calculator (http://
scienceprimer.com/copy-number-calculator-for-realtime-
pcr). All qPCR assays were carried out using Step One™ 
Real-Time PCR System (Applied Biosystems).
Inhibitor assays
For replication assays, cells were seeded in 24-
well plates at 1 x 105 cells/well and for western blotting 
in 60 mm dishes at 2 x 105 cells/dish. Plates were then 
treated with one of the following inhibitors; salirasib 
[10 µM] (Sigma), p38 inhibitor IV [10 µM] (Sigma) or 
PD 184352 [1 µM] (Selleck), 1 hour before irradiation at 5 
Gy. Cells were infected with RT3D (MOI 5) 4 hours after 
irradiation. One-step growth curves and western blotting 
were carried out as described.
Confocal imaging
Cells were seeded at 1 x 105 cells/dish, irradiated with 
5 Gy the next day and infected with RT3D (MOI 0.01). 
Cells were incubated at 37°C for 48 hours, and then 100 nM 
Mitotracker (Cell signalling) was added to each plate and 
incubated at 37°C for 15 min. The Mitotracker was removed 
and replaced with fresh growth medium and incubated at 
37°C for 1 hour. Cells were fixed in 4% paraformaldehyde 
(PFA) at 37°C for 10 min, washed in PBS (3 x 5 mins), 
permeabilized with 0.2% Triton X-100 (Sigma) in PBS 
for 20 min and washed in PBS 3 times. Cells were then 
blocked in immunofluorescence buffer (IFF; PBS, 1% 
BSA, 2% FBS and 0.05% sodium azide) for 1 hour at room 
temperature and incubated overnight with primary antibody 
(1:200). Secondary Alexa fluor (1:1000 Life Technologies) 
was added and incubated at room temperature for 90 min. 
Cells were washed in PBS once for 5 min. Images were 
taken using a Zeiss Zen 2009 confocal system.
Apoptosis array
Cell lysates were obtained from A375 cells, after 
72hrs post-treatment. The expression of 35 apoptosis-
related proteins was analysed using the antibody-based 
Proteome Profiler™ Apoptosis Array from R&D Systems 
(Cat No. ARY009) as per manufacturer’s instructions.
Western blotting
Cells were plated at 2 × 105 in 60 mm dishes. 
Following various treatments, cells were harvested 
in ice-cold PBS, pelleted and re-suspended in 
radioimmunoprecipitation assay buffer [50 mM Tris (pH 
7.5), 150 mM NaCl, 1% NP40, 0.5% sodium deoxycholate, 
and 0.1% SDS] with protease inhibitors (Roche Diagnostics 
GmbH, Mannheim, Germany), 1 mM sodium orthovanadate 
(Sigma), and 10 mM sodium fluoride. Cells were then 
lysed by snap freezing on dry ice and allowing the lysate 
to thaw on ice for 10 minutes before centrifugation at 
13,200 rpm/4°C for 20 minutes to remove cell debris. 
Protein concentration was determined using the BCA 
protein assay (Pierce, Rockford, IL). Twenty-five μg of 
each protein sample were resolved on SDS-polyacrylamide 
gels (10-12%) and transferred to a polyvinylidene difluoride 
Hybond-P membrane (Amersham, Buckinghamshire, 
United Kingdom). The membrane was blocked with 
5% milk in Tris-buffered saline with Tween 20 at room 
temperature for 1 hour incubated overnight at 4°C with 
primary antibody. Primary antibodies for all proteins were 
obtained from Cell Signalling, except the following: smac/
diablo (Abcam), pan Ras (biorybt), pPKR (Santa Cruz 
Biotechnologies), CUG2 (ProSciΨ™), reo µ1c 10F6 and 
sigma 3 4F2, (Developmental Studies Hybridoma Bank). 
Equal loading was assessed using a-tubulin (Sigma Aldrich), 
β-actin (Abcam) or GAPDH (Cell Signaling) mouse 
monoclonal primary antibodies. Blots were developed using 
secondary antibody conjugated to horseradish peroxidase 
(1:5000; GE Healthcare) and visualized using Super Signal 
chemiluminescent system (Pierce) or Immobilon Western 
chemiluminescent HRP substrate (Millipore).
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In vivo studies
A375 tumours were established in female CD1 
nude mice by subcutaneous (s.c) injection of 3 × 106 cells 
suspended in 100 µL PBS in the left flank. Once xenografts 
had reached approximately 5 mm in diameter, mice were 
randomly allocated to treatment groups (10 mice per 
group) before beginning therapy, prior to irradiation. 
Anesthetized animals (I.P. injection of 100 μL of a 
1:10:20 mixture of ketamine (Vetalur 100mg/ml), xylazine 
(Rompin 2%) and water for injection BP (Fresenius Health 
Care Group)) were positioned with tumours exposed under 
an aperture in 3-mm lead shielding and irradiated for a 
total dose of 6 Gy in 3 fractions over 5 days. RT3D was 
administered by intra-tumoral injection 1 hour before the 
second fraction of radiation. Tumors were harvested from 
one mouse in each group after 5 days treatment. Tumours 
from the remaining mice were measured twice weekly in 
two dimensions using Vernier callipers and the volume 
estimated using the formula (length2 × width)/2. Humane 
endpoint was defined as a tumor diameter greater than 12 
mm in any dimension.
Statistical analysis
Comparisons between groups were done using the 
two-way ANOVA (in vitro analysis). P values <0.05 were 
considered to be statistically significant (*, P < 0.05; **, 
P < 0.01; ***, P < 0.005). All plots were generated using 
Prism Graph Pad software. Survival analysis was done 
using Prism Graph pad software and log-rank test was 
used to calculate p value.
The MTT data was analyzed for synergy between 
different treatments by Bliss Independence Analysis as 
described previously [34]. Briefly, the Bliss formulae is 
as follows; EIND = EA + EB – EA x EB and ΔE = EOBS – 
EIND; where EA and EB are the fractional effects of factors 
A and B (in this case RT3D and RT), EIND is the expected 
effect of the independent combination of factors and 
EOBS is the observed effect of the combination. The ΔE 
values were classified as follows; > 0 synergy present, 
< 0 antagonism present or = 0 the combination was 
independent.
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